The Complete Wegovy Guide: STEP Trial Results, Cardiovascular Benefits, Dosing, Cost & Access

Wegovy is the brand name for semaglutide 2.4 mg, manufactured by Novo Nordisk and FDA-approved in June 2021 for chronic weight management in adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidemia. In December 2022, Wegovy also received FDA approval for adolescents aged 12 and older with a BMI at or above the 95th percentile for their age and sex, reflecting the growing recognition of the pediatric and adolescent obesity crisis in the United States.

Wegovy was a watershed moment in the history of obesity medicine. While Ozempic (semaglutide for diabetes) had been approved since 2017 and physicians had observed its weight loss effects, Wegovy represented the first time semaglutide was rigorously evaluated and approved at a dose specifically optimized for maximum weight loss — 2.4 mg weekly, which is higher than Ozempic's maximum dose of 2 mg. This distinction matters clinically because trial data demonstrates that the 2.4 mg dose produces meaningfully more weight loss than lower doses, with a clear and consistent dose-response relationship across patient populations.

In March 2024, Wegovy received an expanded FDA indication for cardiovascular risk reduction in overweight or obese adults with established cardiovascular disease — a truly historic milestone in obesity medicine. This made Wegovy the first anti-obesity medication in history to be FDA-approved for reducing the risk of heart attack, stroke, and cardiovascular death, based on the landmark SELECT trial data. This expanded indication fundamentally changed how obesity treatment is perceived in mainstream medicine, repositioning it as a serious cardiovascular intervention rather than merely a cosmetic or lifestyle concern.

Wegovy's approval was based on the STEP (Semaglutide Treatment Effect in People with Obesity) clinical trial program, one of the largest and most rigorous obesity medication trial programs ever conducted. Over 10,000 participants were enrolled across multiple randomized, double-blind, placebo-controlled studies conducted at hundreds of sites worldwide, providing an exceptionally robust evidence base.

The headline result came from STEP 1, the pivotal trial: participants without diabetes who received semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% with placebo — a six-fold difference. For a 250-pound person, 14.9% translates to approximately 37 pounds of weight loss. In the same trial, 86% of participants lost at least 5% of body weight, 69% lost at least 10%, and one-third lost at least 20% — each of these thresholds is associated with clinically documented improvements in blood pressure, blood sugar control, cholesterol levels, liver fat, joint pain, and sleep apnea severity.

STEP 2 focused on patients with both obesity and type 2 diabetes, showing 9.6% average weight loss. Weight loss tends to be lower in diabetic populations due to metabolic factors including hyperinsulinemia and greater metabolic resistance. STEP 3 combined semaglutide with intensive behavioral therapy — including meal replacements, food logging, and weekly counseling sessions — and demonstrated 16% average weight loss, illustrating the added value of structured lifestyle support alongside medication. STEP 4 was particularly informative for long-term planning: it demonstrated that patients who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight within the following year, while those who continued medication maintained and extended their weight loss — powerfully underscoring the importance of sustained treatment for maintaining results.

The SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial was a landmark study that fundamentally changed how the medical community, insurers, and policymakers perceive obesity medication. This randomized, double-blind, placebo-controlled trial enrolled over 17,600 overweight or obese adults aged 45 and older with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) but crucially, without diabetes — isolating the cardiovascular effects of weight management from diabetes treatment.

The primary result was striking: semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) — a composite endpoint of cardiovascular death, non-fatal heart attack, and non-fatal stroke — by 20% compared to placebo over a median follow-up period of 40 months. This was a statistically significant and clinically meaningful reduction that met the trial's pre-specified primary endpoint. The benefit was consistent across subgroups regardless of age, sex, baseline BMI, or geographic region.

What made SELECT groundbreaking was that it definitively proved an anti-obesity medication could reduce hard cardiovascular endpoints — actual heart attacks, strokes, and deaths — independently of diabetes treatment. Previous cardiovascular outcomes trials with GLP-1 medications (SUSTAIN 6 with semaglutide, LEADER with liraglutide) had focused exclusively on patients with type 2 diabetes. SELECT demonstrated that the cardiovascular benefits extend to the broader, much larger population of people with obesity and established heart disease. This finding led directly to Wegovy's expanded FDA indication and has accelerated insurance coverage decisions across the industry, as payers increasingly recognize the medication's potential to prevent costly cardiovascular hospitalizations and events.

Wegovy's dose escalation schedule begins at 0.25 mg weekly for weeks 1 through 4, increases to 0.5 mg for weeks 5 through 8, then to 1.0 mg for weeks 9 through 12, followed by 1.7 mg for weeks 13 through 16, and finally reaches the full maintenance dose of 2.4 mg from week 17 onward. Each dose is administered via a single-dose prefilled pen — unlike the multi-dose Ozempic pen, each Wegovy pen is used once for a single injection and then disposed of. The pens come pre-set to the correct dose, requiring no dialing.

The most common side effects in the STEP clinical trials were gastrointestinal in nature: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain (20%). These rates are higher than those seen with lower-dose Ozempic because Wegovy reaches a higher maximum dose of 2.4 mg. However, the gradual five-step escalation schedule means that most patients experience GI symptoms transiently during each dose increase rather than continuously throughout treatment — symptoms typically peak in the first three to seven days after each increase and then subside.

Approximately 7% of participants in the STEP trials discontinued Wegovy due to adverse events — meaning 93% were able to continue treatment with manageable or resolved side effects. Serious but rare risks include pancreatitis (less than 0.5%), gallbladder disease (1.6% vs. 0.7% on placebo — consistent with rapid weight loss from any method), and the theoretical thyroid tumor concern shared by all GLP-1 medications (boxed warning based on rodent studies). The cardiovascular benefit demonstrated in the SELECT trial provides strong additional evidence that for eligible patients, Wegovy's demonstrated health benefits substantially outweigh its known risks.

Wegovy's list price is approximately $1,300 to $1,350 per month without insurance coverage. This price point has been one of the biggest barriers to widespread access since the medication's launch, as many insurance plans initially excluded anti-obesity medications from their formularies entirely, viewing weight management as elective rather than medically necessary. However, the landscape is shifting significantly following the SELECT cardiovascular trial results and the expanded FDA indication for heart disease risk reduction.

A growing number of commercial insurers and employer-sponsored health plans now cover Wegovy, particularly for patients with established cardiovascular disease, type 2 diabetes, or multiple obesity-related comorbidities. Medicare Part D began expanding coverage for anti-obesity medications following legislative advocacy and the recognition that preventing cardiovascular events through weight management is more cost-effective than treating them after they occur. Coverage typically requires prior authorization and documentation of BMI, relevant comorbidities, and in some cases evidence of prior diet and exercise attempts. Commercial insurance copays for covered patients range widely from $25 to several hundred dollars per month depending on plan specifics.

For patients without adequate insurance coverage, several alternatives exist. Novo Nordisk offers a patient savings program that can reduce costs for eligible commercially insured patients, though program terms change periodically. Compounded semaglutide provides the same active ingredient at a substantially lower price point — at Weight Method, semaglutide subscriptions start at $297 per month, which includes the medication, comprehensive physician evaluation, personalized dosing guidance, and ongoing clinical support throughout treatment. This makes the proven benefits of semaglutide treatment accessible to a much broader population than brand-name Wegovy pricing alone would allow.